Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668382 · ClinicalTrials.gov registry record · Phase 1
Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection
A Phase 1 study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00668382 is a Phase 1 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 11 participants.
The verdict
NCT00668382, a Phase 1 study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a Phase I pilot study to evaluate the toxicity and feasibility of intratumoral injection (Glycosphingolipids) GSL alpha-GAL (beta-galactosidase) in patients with advanced, refractory solid tumors who have failed standard therapies or are not eligible for standard treatment.
Interventions
- BIOLOGICAL Alpha-Gal Glycosphingolipid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00668382
The ClinicalTrials.gov registry entry for NCT00668382 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alpha-Gal Glycosphingolipid is the first listed.
NCT00668382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00668382 about?
NCT00668382 is a clinical study titled "Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection". This is a Phase I pilot study to evaluate the toxicity and feasibility of intratumoral injection (Glycosphingolipids) GSL alpha-GAL (beta-galactosidase) in patients with advanced, refractory solid tumors who have failed standard therapies or are not eligible for standard treatment.
What is the current status of trial NCT00668382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2007-07. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00668382?
The interventions under investigation include: Alpha-Gal Glycosphingolipid (BIOLOGICAL).
Who is sponsoring clinical trial NCT00668382?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.